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Forward-Looking Statements and Disclaimers
• This presentation contains forward-looking information and statements which constitute “forward-
looking information” under Canadian securities law and which may be material regarding, among 
other things, the Company’s beliefs, plans, objectives, estimates, intentions and expectations. 
Forward-looking information and statements are typically identified by words such as 
“anticipate”, “believe”, “expect”, “estimate”, “forecast”, “goal”, “intend”, “plan”, “will”, “may
”, “should”, “could” and similar expressions. Specific forward-looking information in this document 
includes, but is not limited to, statements with respect to the Company’s future operating and 
financial results, its research and development activities, its capital expenditure plans and the 
ability to execute on its future operating, investing and financing strategies.  These forward-
looking information and statements, by their nature, necessarily involve risks and uncertainties 
that could cause actual results to differ materially from those contemplated by these forward-
looking statements. We consider the assumptions on which these forward-looking statements are 
based to be reasonable, but caution the reader that these assumptions regarding future 
events, many of which are beyond our control, may ultimately prove to be incorrect since they are 
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subject to risks and uncertainties that affect us.  Additional information regarding risk factors can 
be found in the Medicago Annual Information Form filed on March 29, 2012.
• Our statements of “belief” in respect of our product and partner product candidates are based
primarily upon our results derived to date from our research and development program. We believe
that we have a reasonable scientific basis upon which we have made such statements. It is not
possible, however, to predict, based upon studies in vitro and animal studies whether a new
therapeutic agent or technology will be proved to be safe and/or effective in humans. We cannot
assure that the particular results expected by us will occur.
• Any forward-looking statements and statements of “belief” represent our estimates only and
should not be relied upon as representing our estimates as of any subsequent date. Except as
required by law, we do not assume any obligation to update any forward looking statements or
statements of “belief”. We disclaim any intention or obligation to update or revise any forward-
looking statements or statements of “belief”, whether as a result of new information, future
events or otherwise. Nothing herein should be construed as an Offering of securities of the
Company in any jurisdictions.
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Reengineering vaccine design and production 
(beyond pandemic)
• Strains with pandemic potential are circulating every year; 
experts agree only a matter of time before a highly lethal 
strain develops due to strain mutations
– Kawaoka’s & Fouchier’s studies
• Rapid response in pandemic vaccine production is needed to 
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address rapid rates of infection & minimize deaths
– In 2009 pandemic, time required to manufacture both egg- & 
cell-based vaccines resulted in “too little, too late” vaccine 
responses  no significant impact*
• Need for flexible technologies to respond to emerging or 
engineered biothreats
– Multi-product platform




Focus Vaccines & Protein-based pharmaceuticals
Manufacturing technology Transient expression in Tobacco
Vaccine technology Virus-like particles
Vaccine discovery platform VLPExpress
Headquarters, laboratories & 
Quebec City, CANADA
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cGMP facilities
Research Triangle Park, NC, USA
Genopole d’Evry, FRANCE
Agreements
Mitsubishi Tanabe Pharma – Strategic Alliance
DARPA  Award – US$21M 
IDRI – Phase I H5 GLA, intradermal
Pharma & U.S. Army – Vaccines outside of flu
$35M & 12 months to build
Capacity of 10M doses/month
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Protalix is paving the way…
First plant-derived pharmaceutical approved by FDA on 
May 1st, 2012




Proprietary platform for the production recombinant proteins based on 
a transient expression technology in plants (N. benthamiana)
Plants & Agrobacterium 





Medicago VLP Influenza virus
Extraction
• 19 days to 1st lot
• Rapid lot-release:
• HA content
• 14-days sterility test
preparation
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Characteristics of the plant-made H5 VLP vaccine
• Lot-release assays include purity, potency by SRID, lipid and protein
content, residual DNA, endotoxins, nicotine and anabasine content, 
sterility
• Additional characterization such as SEC, NTA, MFI, PDI, glycans















































































































































































































































































Similar profiles were observed for systemic AEs
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Safety
IgE to plant glycans
Clinical trial Group Number of 
subjects with 












6 months after 
vaccination
Phase 1 with 










Fluzone 0% 0% 0%
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Phase 2 with 
























• No onset of allergic reactions correlating with in vitro assay
(manuscript in preparation)
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Antibody response – H5 VLP
HI test
H5 VLP Vaccine









Seroconversion rate after two doses of H5 VLP (18-64 years of age)
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Phase I*







Phase II (part 












Antibody response – H5 VLP 
Phase II trial part B
Seroconversion rates after two doses
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HI test 56.5% 45.5% 38.5% 50.0%
SRH test 52.2% 40.9% 50.0% 42.3%
MN test 52.2% 50.0% 50.0% 50.0%
All vaccine doses statistically different from placebo
H5 VLP vaccine equally immunogenic in young and older adults
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Duration of antibody response – H5 VLP
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20 + alum 0 23,3 75,9 69,0
30 + alum 0 24,1 75,0 50,0
45 + alum 0 23,3 73,3 60,0
45 0 10,7 64,3 40,7
Placebo 0 0 0 8,0
Alum showed benefit on the antibody level for the H5 VLP vaccine 
although formulation not optimized at high vaccine dosages
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H1 VLP Vaccine (groups of 20 subj.)
5 µg 13 µg 28 µg
Antibody response – H1 VLP
HI test
Seroconversion rate after one single non-adjuvanted dose of H1 VLP 
(18-49 years of age)







































H1 VLP Vaccine Induced a Long Lasting 
Memory Multifunctional T cell Response






































































H1 VLP Vaccine Induces Cross-Reactive CD4+ T cell 
Responses against HA (H5N1)
Total CD4+ T cell response against HA (H1N1) :
• PBMC at +6 month post-vaccine


















































obtained for CD8+ 
T cell responses
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Main conclusions from clinical trials
• Safety
– Safe and well tolerated
– More than 400 subjects dosed
– 1 or 2 doses
– With or without alum
– Dosages up to 45 µg
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– No onset of allergic reactions
• Immunogenicity
– The HA-VLP vaccine induces durable antibody response
– Durable, poly-functional and cross-reactive T Cell 
responses to influenza HA antigens
– Strong innate immune response induced (data not shown)
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• Can the manufacturing and vaccine platforms also 
produce VLPs presenting non-influenza antigens?
– different genomic organization (RNA, DNA, polyprotein…)
– different envelope proteins structure
– different budding sites and requirements
Expanding the applications of the manufacturing 
and vaccine platforms




Hepatitis C Human papillomavirus
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VLPExpress: Accelerating the discovery of VLP-
based vaccines
• Scale-down of manufacturing 
technology
– HT cloning (96 DNA constructs in 
10 days)
– Automated HT infiltration (50 
expression strategies/days)
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– HT monitoring of viral protein and 
VLP accumulation
– Generic purification method
• Screening 
– Capacity improved 10X 
– Time to identification 10X faster
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Flexibility: 
Broadening applications of manufacturing & vaccine platforms
• Throughput of VLPExpress enables running multiple projects in parallel
• In 2011, the discovery team has tested >2,000 engineering approaches 
and identified those driving the assembly of VLPs for 7 different families 
of viruses:
– Influenza (including 20 sub-types)
– Rabies
– Proprietary undisclosed  enveloped VLP





– Partnered undisclosed capsid VLP
• Advantages
– Testing of multiple expression vectors in parallel
– Comparing different protein engineering strategies
– Co-expressing various proteins using separate Agrobacteria
– Rapid optimization of expression conditions
– Allow development of vaccines with "built-in" efficacy and manufacturing 
readiness
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Advantages of Medicago’s plant-based technology
• Pandemic
– Target any HA sequence including wild-type
– Induce strong antibody responses
– Induce a balanced immune response
• Strong CD4+ and CD8+ memory
• Cross-reactive for other strains
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– More durable strain-specific immunity
– Superior cross-reactivity
– Possible role in the elderly
• Other emerging threats
– Many features of plant-made influenza VLPs vaccines 
applicable to other indications (natural or man-made)




Research and Innovation team
Product Development team
Manufacturing and QA teams 
Collaborators
GLA adjuvanted vaccine
From IDRI: Darrick Carter Patti Hon        Anthony Desbien
Steve Reed Rhea Coler
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Sponsors
Susan Baldwin Chris Fox
From CSU (animal studies): Richard Bowen
Cell-mediated Immune response
ImmuneCarta: David Favre
McGill University: Brian J. Ward’s team
Obrigada!
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